Content Reproduced verbatim from the Website of FindLaw, A Thomson Reuters Business, as permitted under their RSS FEEDS, Terms of Use.

Sanofi v. Watson Laboratories Inc., 16-2722

Affirming the district court’s rulings in the case of a patent infringement claim relating to cardiovascular drugs where the court held that the plaintiff had proven that the defense’s sale of proposed generic drugs with their proposed labels would induce physicians to infringe, and holding that none of the patents were invalid for obviousness.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/11/09



  • United States Federal Circuit


Twitter Auto Publish Powered By :